ADPT
- Adaptive Biotechnologies Corporation
()
Overview
Company Summary
Adaptive Biotechnologies Corporation (ADPT) is a company that specializes in using the power of the immune system to develop innovative diagnostic and therapeutic solutions for various diseases. Specifically, Adaptive Biotechnologies focuses on harnessing the potential of the adaptive immune system, which is responsible for recognizing and defending the body against specific threats such as infections and cancers.
The company has developed a proprietary technology platform called immunoSEQ, which enables the comprehensive profiling of T-cell and B-cell receptors at the genetic level. By analyzing the unique receptors present on these immune cells, Adaptive Biotechnologies can gain valuable insights into the immune response of an individual.
Adaptive Biotechnologies applies this deep understanding of the immune system to develop diagnostic solutions that can assess a patient's immune response to various diseases. This includes the ability to identify specific infections, monitor diseases such as cancer, and evaluate the effectiveness of immunotherapies.
One notable application of Adaptive Biotechnologies' technology is in the field of oncology. By analyzing the T-cell receptors, the company can create personalized tests known as clonoSEQ. These tests help clinicians detect and monitor minimal residual disease (MRD) in patients with blood cancers, enabling more precise treatment decisions and improved patient outcomes.
In addition to diagnostics, Adaptive Biotechnologies also collaborates with pharmaceutical and biotechnology companies to develop novel immune-based therapeutics. By leveraging the immune receptor data gathered through its immunoSEQ platform, the company can identify potential therapeutic targets and gain insights into patient responses to treatment.
Overall, Adaptive Biotechnologies Corporation focuses on unlocking the potential of the immune system to improve patient care. Through its advanced technology platform and collaborations, the company aims to provide innovative solutions for diseases where immune profiling can make a significant impact, ultimately leading to more effective treatments and better patient outcomes.